1. |
Inki P, Joensuu H, Grenman R, et al. Association between syndecan1 expression and clinical outcome in squamous cell carcinoma of the head and neck 〔J〕. Br J Cancer, 1994; 70(2)∶319.
|
2. |
Bernfield M, Kokenyesi P, Kato M, et al. Biology of the syndecans 〔J〕. Ann Rev Biochem, 1992; 8∶365.
|
3. |
Roskams T, Moshage H, De Vos R, et al. Heparan sulfate proteoglycan expression in normal human liver 〔J〕. Hepatology, 1995; 21(4)∶950.
|
4. |
Roskams T, De Vos R, David G, et al. Heparan sulphate proteoglycan expression in human primary liver tumors 〔J〕. J Pathol, 1998; 185(3)∶290.
|
5. |
Matsumoto A, Ono M, Fujimoto Y, et al. Reduced expression of syndecan1 in human hepatocellular carcinoma with high metastatic potential 〔J〕. Int J Cancer, 1997; 74(5)∶482.
|
6. |
Mali M, Andfolk H, Miettinen HM, et al. Suppression of tumor cell growth by syndecan1 ectodomain 〔J〕. J Biol Chem, 1994; 269(45)∶27795.
|
7. |
KumarSingh S, Jacobs W, Dhaene K, et al. Syndecan1 expression in maligant mesothlioma: correlation with differentiation, wtl expression, and clinical outcome 〔J〕. J Pathol, 1998; 186(3)∶300.
|
8. |
Izumi R, Shimizu K, Li T, et al. Prognostic factors of hepatocellular carcinoma in patients undergoing hepatic resection 〔J〕. Gastroenterology, 1994; 106(3)∶720.
|